查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1766158

嗜酸性粒細胞藥物市場預測（至 2032 年）：按藥物類別、疾病類型、給藥途徑、分銷管道、最終用戶和地區進行的全球分析

Eosinophilia Therapeutics Market Forecasts to 2032 - Global Analysis By Drug Class, Disease Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球嗜酸性粒細胞治療藥物市場預計在 2025 年達到 4.543 億美元，到 2032 年將達到 7.247 億美元，預測期內的複合年成長率為 6.9%。

嗜酸性粒細胞藥物包括用於控制由過敏性疾病、寄生蟲感染疾病以及某些疾病（例如嗜酸性細胞增多症(HES) 和嗜酸性粒細胞氣喘）引起的嗜酸性粒嗜酸性粒細胞水平升高的治療。治療方法包括皮質類固醇、免疫抑制劑以及標靶生技藥品，例如抗 IL-5、抗 IL-4Ra 和抗 IgE 單株抗體。這些療法旨在透過調節潛在的免疫反應來減少嗜酸性粒細胞發炎、預防器官損傷並改善患者預後。

根據歐洲藥品管理局（EMA）的數據，嗜酸性粒細胞增多症（HES）的盛行率為每十萬人1.5人。

嗜酸性粒細胞增多症盛行率不斷上升

嗜酸性粒細胞增多症盛行率的上升是主要促進因素。這一成長歸因於診斷能力的提高，使得罕見嗜酸性粒細胞症相關疾病能夠早期發現，以及導致過敏性和發炎性疾病的環境因素增加。醫療保健專業人員臨床意識的提高，提高了對嗜酸性粒細胞細胞性氣喘、嗜酸性粒細胞細胞增多症候群和嗜伊紅性食道炎的認知。患者群體的不斷擴大帶來了對標靶治療的巨大需求，促使製藥公司大力投資研發針對這些複雜免疫疾病的專門治療方法。

新藥高成本

儘管單株抗體和標靶生技藥品有效，但其高昂的價格限制了患者在整個醫療保健系統中的可及性和採用率。這些治療方法的特殊性需要大量的臨床試驗和核准流程，導致高昂的開發成本最終轉嫁給消費者。保險覆蓋範圍的限制和報銷挑戰進一步限制了市場滲透，尤其是在醫療預算有限的新興國家，從而導致不同患者群體在治療可及性方面存在差異。

下一代生技藥品和精準醫療的開發

精準醫療方法的進展以及針對IL-5、IL-4和IL-13等特定路徑的創新生技藥品展現出巨大的市場潛力。針對嗜酸性粒細胞的新型療法的臨床試驗正在進行中，這拓展了傳統皮質類固醇以外的治療選擇。此外，個人化醫療策略能夠根據患者個別情況制定個人化治療方案，從而改善治療效果並減少副作用。對嗜酸性粒細胞疾病機制的深入了解將推動更具針對性的療法的開發，為製藥公司提供透過差異化產品滿足未滿足的醫療需求來搶佔市場佔有率的機會。

生物相似藥的興起

隨著原廠單株抗體專利到期，生物相似藥製造商能夠提供更具成本效益的替代品，這可能會削弱原廠公司的市場佔有率。此外，隨著監管機構簡化生物相似藥的核准途徑，生物相似藥正加速進入市場，增加了創新藥公司的競爭壓力。這種威脅可能導致價格競爭加劇，利潤率受到擠壓，迫使原廠製造商在日益商品化的治療環境中展示卓越的臨床價值或開發下一代療法。

COVID-19的影響

COVID-19 疫情導致診斷延遲和常規醫療護理推遲，對嗜酸性粒細胞藥物市場產生了重大影響。由於醫療系統優先應對疫情，嗜酸性粒細胞細胞增多症的篩檢減少，影響了醫療的連續性。然而，這場危機加速了遠端醫療和數位健康整合的普及，創造了新的病人參與管道。此外，疫情期間人們對呼吸系統疾病的關注度不斷提高，也提高了人們對嗜酸性粒細胞氣喘的認知，隨著醫療服務恢復正常化，這可能會推動未來市場的成長。

預測期內，皮質類固醇市場預計將實現最大幅度成長

預計皮質類固醇藥物將在預測期內佔據最大的市場佔有率，這得益於其在快速控制發炎方面已被證實的有效性，以及其作為各種嗜酸性粒細胞增多症的一線市場佔有率的成熟地位。這些藥物廣泛適用於過敏性、自體免疫和特發性嗜酸性粒細胞增多症，可快速緩解症狀，並可在門診使用。與新型生物製藥相比，皮質類固醇藥物的成本效益更高，因此受到臨床醫生的青睞，尤其是在資源匱乏的醫療環境中，從而確保了其在市場上的持續領先地位。

預計在預測期內，網上藥局領域將以最高的複合年成長率成長。

在預測期內，由於數位醫療的廣泛應用以及越來越多的患者偏好便捷的藥品獲取方式，預計線上藥局領域將呈現最高成長率。數位平台提供增強的患者教育資源、對藥物依從性的支持以及簡化的處方管理系統，從而改善治療效果。此外，新冠疫情加速了電子商務在醫療保健領域的應用，使線上藥局成為傳統零售通路的可行替代方案。此外，這些平台通常提供具有競爭力的價格、宅配服務以及針對慢性病的專業支持，這對於需要長期治療管理和定期藥物補充的嗜酸性粒細胞患者尤其具有吸引力。

比最大的地區

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療基礎設施和基於循證醫學的嗜酸性粒細胞增多症藥物療法的廣泛採用。該地區受益於專注於免疫療法的大型生物製藥公司的強大影響力、健全的法律規範以及支持生物療法的全面保險覆蓋。此外，醫療保健專業人員臨床意識的不斷提高和診斷能力的提升，使得該地區能夠及早發現並有效管理嗜酸性粒細胞細胞增多症。

複合年成長率最高的地區

在預測期內，北美預計將佔據最大的市場佔有率，這得益於全部區域醫療基礎設施的不斷擴大以及人們對過敏和免疫疾病認知的不斷提高。中國、印度和日本等國家由於嗜酸性粒細胞增多症盛行率的上升、診斷能力的提高以及醫療保健支出的不斷成長，是極具潛力的市場。此外，生技藥品和皮質類固醇替代藥物的可近性不斷提高，以及醫生對嗜酸性粒細胞細胞增多症相關知識的不斷普及，正在推動市場的強勁擴張。此外，政府的醫療政策也創造了有利條件，使亞太地區成為成長最快的地區。

免費客製化服務

訂閱此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球嗜酸性粒細胞藥物市場（依藥物類別）

  • 皮質類固醇
  • 單株抗體（生技藥品）
    • 抗IL-5/IL-5Ra
    • 抗IL-4Ra
    • 抗IgE
    • 其他
  • 免疫抑制劑
    • 羥基尿素
    • 干擾素-α
    • Imatinib
  • 質子幫浦抑制劑（PPI）
  • 其他

6. 全球嗜酸性粒細胞治療市場（依疾病類型）

  • 嗜酸性粒細胞症（HES）
  • 嗜伊紅性食道炎（EoE）
  • 嗜酸性粒細胞氣喘
  • 嗜酸性粒細胞肉芽腫性多血管炎（EGPA）
  • 其他

7. 全球嗜酸性粒細胞藥物市場（依給藥途徑）

  • 口服
  • 腸外（注射）
  • 吸入
  • 局部的

8. 全球嗜酸性粒細胞藥物市場（依分銷管道）

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 直銷

9. 全球嗜酸性粒細胞治療市場（依最終用戶）

  • 醫院
  • 專科診所
  • 居家照護環境
  • 其他

第 10 章全球嗜酸性粒細胞治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Allakos, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Cipla Inc.
  • Eli Lilly & Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc（GSK）
  • Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Ltd.
  • Arena Pharmaceuticals Ltd.
  • Ellodi Pharmaceuticals
  • Revolo Biotherapeutics
Product Code: SMRC30014

According to Stratistics MRC, the Global Eosinophilia Therapeutics Market is accounted for $454.3 million in 2025 and is expected to reach $724.7 million by 2032 growing at a CAGR of 6.9% during the forecast period. Eosinophilia therapeutics encompass a range of treatments designed to manage elevated eosinophil levels, which can result from allergic conditions, parasitic infections, or specific disorders like hypereosinophilic syndrome (HES) and eosinophilic asthma. Therapies include corticosteroids, immunosuppressants, and targeted biologics such as anti-IL-5, anti-IL-4Ra, and anti-IgE monoclonal antibodies. These therapeutics aim to reduce eosinophilic inflammation, prevent organ damage, and improve patient outcomes by modulating the underlying immune response.

According to the European Medicines Agency (EMA), the estimated prevalence of hypereosinophilic syndrome (HES) is 1.5 per 100,000 people.

Market Dynamics:

Driver:

Increasing prevalence of eosinophilic disorders

The rising incidence of eosinophilic disorders serves as a primary growth driver. This increase stems from enhanced diagnostic capabilities that enable earlier detection of rare eosinophilia-related conditions, coupled with growing environmental factors contributing to allergic and inflammatory diseases. Heightened clinical awareness among healthcare professionals has led to improved recognition of eosinophilic asthma, hypereosinophilic syndrome, and eosinophilic esophagitis. The expanding patient population creates substantial demand for targeted treatments, driving pharmaceutical companies to invest heavily in research and development of specialized therapies to address these complex immunological conditions.

Restraint:

High cost of novel therapies

Monoclonal antibodies and targeted biologics, while highly effective, command premium pricing that limits patient accessibility and healthcare system adoption. The specialized nature of these therapies requires extensive clinical trials and regulatory approval processes, contributing to elevated development costs that are ultimately passed to consumers. Insurance coverage limitations and reimbursement challenges further restrict market penetration, particularly in emerging economies where healthcare budgets are constrained, creating disparities in treatment access across different patient populations.

Opportunity:

Development of next-generation biologics and precision medicine

The advancement of precision medicine approaches and innovative biologics targeting specific pathways like IL-5, IL-4, and IL-13 represents tremendous market potential. Ongoing clinical trials of novel eosinophil-targeting therapeutic agents are expanding treatment options beyond traditional corticosteroids. Moreover, personalized medicine strategies enable tailored treatment protocols based on individual patient profiles, improving therapeutic outcomes while reducing adverse effects. The growing understanding of eosinophilic disease mechanisms facilitates the development of more targeted interventions, creating opportunities for pharmaceutical companies to capture market share through differentiated products that address unmet medical needs.

Threat:

Emergence of biosimilars

As patents for original monoclonal antibodies expire, biosimilar manufacturers can offer cost-effective alternatives that potentially erode the market share of branded products. Furthermore, regulatory agencies are streamlining approval pathways for biosimilars, accelerating their market entry and increasing competitive pressure on innovator companies. This threat intensifies price competition and may compress profit margins, forcing original manufacturers to demonstrate superior clinical value or develop next-generation therapies in an increasingly commoditized therapeutic environment.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the eosinophilia therapeutics market through delayed diagnoses and postponed routine medical consultations. Healthcare systems prioritized pandemic response, leading to reduced screening for eosinophilic disorders and interrupted treatment continuity. However, the crisis accelerated telemedicine adoption and digital health integration, creating new patient engagement channels. Additionally, heightened focus on respiratory conditions during the pandemic increased awareness of eosinophilic asthma, potentially driving future market growth as healthcare services normalize.

The corticosteroids segment is expected to be the largest during the forecast period

The corticosteroids segment is expected to account for the largest market share during the forecast period due to their proven effectiveness in rapidly controlling inflammation and their established role as first-line therapy for various eosinophilic conditions. These medications offer broad applicability across allergic, autoimmune, and idiopathic eosinophilic disorders while providing fast symptom relief and accessibility in outpatient settings. Their cost-effectiveness compared to newer biologics makes them preferred choices among clinicians, particularly in resource-constrained healthcare environments, ensuring their sustained market leadership.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the online pharmacies segment is predicted to witness the highest growth rate, driven by increasing digital healthcare adoption and patient preference for convenient medication access. Digital platforms offer enhanced patient education resources, medication adherence support, and streamlined prescription management systems that improve treatment outcomes. Moreover, the COVID-19 pandemic accelerated e-commerce adoption in healthcare, establishing online pharmacies as viable alternatives to traditional retail channels. Additionally, these platforms often provide competitive pricing, home delivery services, and specialized support for chronic conditions, making them particularly attractive for eosinophilia patients requiring long-term therapeutic management and regular medication refills.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure and high adoption rates of evidence-based pharmacological therapies for eosinophilic disorders. The region benefits from the strong presence of key biopharmaceutical companies specializing in immunological treatments, robust regulatory frameworks, and comprehensive insurance coverage supporting biologic therapies. Furthermore, heightened clinical awareness among healthcare professionals and superior diagnostic capabilities enable early detection and effective management of eosinophil-associated diseases in the region.

Region with highest CAGR:

During the forecast period, the North America region is expected to hold the largest market share due to expanding healthcare infrastructure and increasing awareness of allergic and immunological disorders across the region. Countries like China, India, and Japan represent high-potential markets due to the growing prevalence of eosinophilic diseases, improved diagnostic capabilities, and rising healthcare expenditure. Additionally, enhanced access to biologics and corticosteroid alternatives, combined with growing physician education on eosinophilic disorders, drives strong market expansion. Moreover, government healthcare policies create favorable conditions, positioning Asia Pacific as the fastest growing region.

Key players in the market

Some of the key players in Eosinophilia Therapeutics Market include Allakos, Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Cipla Inc., Eli Lilly & Company, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Arena Pharmaceuticals Ltd., Ellodi Pharmaceuticals, and Revolo Biotherapeutics.

Key Developments:

In May 2025, GSK plc announced that the US Food and Drug Administration (FDA) have approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. FDA's approval was based on data from the positive MATINEE and METREX phase III trials. Across these trials, mepolizumab showed a clinically meaningful and statistically significant reduction in the annualised rate of moderate/severe exacerbations versus placebo in a wide spectrum of COPD patients with an eosinophilic phenotype.

In May 2025, AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from 16 to 21 May 2025. With more than 75 abstracts, including eight late-breakers, the Company continues to drive innovation and address unmet needs in care across all severities of asthma, chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis (EGPA) and other chronic inflammatory diseases.

In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.

Drug Classes Covered:

  • Corticosteroids
  • Monoclonal Antibodies (Biologics)
  • Immunosuppressants
  • Proton Pump Inhibitors (PPIs)
  • Other Drug Classes

Disease Types:

  • Hypereosinophilic Syndrome (HES)
  • Eosinophilic Esophagitis (EoE)
  • Eosinophilic Asthma
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • Other Eosinophilic Disorders

Route of Administrations:

  • Oral
  • Parenteral (Injectable)
  • Inhalation
  • Topical

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Direct Distribution

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Other Healthcare Facilities

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Eosinophilia Therapeutics Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Corticosteroids
  • 5.3 Monoclonal Antibodies (Biologics)
    • 5.3.1 Anti-IL-5/IL-5Ra
    • 5.3.2 Anti-IL-4Ra
    • 5.3.3 Anti-IgE
    • 5.3.4 Other Emerging Biologics
  • 5.4 Immunosuppressants
    • 5.4.1 Hydroxyurea
    • 5.4.2 Interferon-a
    • 5.4.3 Imatinib
  • 5.5 Proton Pump Inhibitors (PPIs)
  • 5.6 Other Drug Classes

6 Global Eosinophilia Therapeutics Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Hypereosinophilic Syndrome (HES)
  • 6.3 Eosinophilic Esophagitis (EoE)
  • 6.4 Eosinophilic Asthma
  • 6.5 Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • 6.6 Other Eosinophilic Disorders

7 Global Eosinophilia Therapeutics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral (Injectable)
  • 7.4 Inhalation
  • 7.5 Topical

8 Global Eosinophilia Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Direct Distribution

9 Global Eosinophilia Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Specialty Clinics
  • 9.4 Homecare Settings
  • 9.5 Other Healthcare Facilities

10 Global Eosinophilia Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Allakos, Inc.
  • 12.2 AstraZeneca plc
  • 12.3 Bayer AG
  • 12.4 Bristol-Myers Squibb
  • 12.5 Cipla Inc.
  • 12.6 Eli Lilly & Company
  • 12.7 Gilead Sciences, Inc.
  • 12.8 GlaxoSmithKline plc (GSK)
  • 12.9 Hoffmann-La Roche Ltd.
  • 12.10 Merck & Co., Inc.
  • 12.11 Novartis AG
  • 12.12 Pfizer Inc.
  • 12.13 Regeneron Pharmaceuticals, Inc.
  • 12.14 Sanofi S.A.
  • 12.15 Takeda Pharmaceutical Company Ltd.
  • 12.16 Arena Pharmaceuticals Ltd.
  • 12.17 Ellodi Pharmaceuticals
  • 12.18 Revolo Biotherapeutics

List of Tables

  • Table 1 Global Eosinophilia Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Eosinophilia Therapeutics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Eosinophilia Therapeutics Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 4 Global Eosinophilia Therapeutics Market Outlook, By Monoclonal Antibodies (Biologics) (2024-2032) ($MN)
  • Table 5 Global Eosinophilia Therapeutics Market Outlook, By Anti-IL-5/IL-5Ra (2024-2032) ($MN)
  • Table 6 Global Eosinophilia Therapeutics Market Outlook, By Anti-IL-4Ra (2024-2032) ($MN)
  • Table 7 Global Eosinophilia Therapeutics Market Outlook, By Anti-IgE (2024-2032) ($MN)
  • Table 8 Global Eosinophilia Therapeutics Market Outlook, By Other Emerging Biologics (2024-2032) ($MN)
  • Table 9 Global Eosinophilia Therapeutics Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 10 Global Eosinophilia Therapeutics Market Outlook, By Hydroxyurea (2024-2032) ($MN)
  • Table 11 Global Eosinophilia Therapeutics Market Outlook, By Interferon-a (2024-2032) ($MN)
  • Table 12 Global Eosinophilia Therapeutics Market Outlook, By Imatinib (2024-2032) ($MN)
  • Table 13 Global Eosinophilia Therapeutics Market Outlook, By Proton Pump Inhibitors (PPIs) (2024-2032) ($MN)
  • Table 14 Global Eosinophilia Therapeutics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 15 Global Eosinophilia Therapeutics Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 16 Global Eosinophilia Therapeutics Market Outlook, By Hypereosinophilic Syndrome (HES) (2024-2032) ($MN)
  • Table 17 Global Eosinophilia Therapeutics Market Outlook, By Eosinophilic Esophagitis (EoE) (2024-2032) ($MN)
  • Table 18 Global Eosinophilia Therapeutics Market Outlook, By Eosinophilic Asthma (2024-2032) ($MN)
  • Table 19 Global Eosinophilia Therapeutics Market Outlook, By Eosinophilic Granulomatosis with Polyangiitis (EGPA) (2024-2032) ($MN)
  • Table 20 Global Eosinophilia Therapeutics Market Outlook, By Other Eosinophilic Disorders (2024-2032) ($MN)
  • Table 21 Global Eosinophilia Therapeutics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 22 Global Eosinophilia Therapeutics Market Outlook, By Oral (2024-2032) ($MN)
  • Table 23 Global Eosinophilia Therapeutics Market Outlook, By Parenteral (Injectable) (2024-2032) ($MN)
  • Table 24 Global Eosinophilia Therapeutics Market Outlook, By Inhalation (2024-2032) ($MN)
  • Table 25 Global Eosinophilia Therapeutics Market Outlook, By Topical (2024-2032) ($MN)
  • Table 26 Global Eosinophilia Therapeutics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 27 Global Eosinophilia Therapeutics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 28 Global Eosinophilia Therapeutics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 29 Global Eosinophilia Therapeutics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 30 Global Eosinophilia Therapeutics Market Outlook, By Direct Distribution (2024-2032) ($MN)
  • Table 31 Global Eosinophilia Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Eosinophilia Therapeutics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 33 Global Eosinophilia Therapeutics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 34 Global Eosinophilia Therapeutics Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 35 Global Eosinophilia Therapeutics Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.